Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Fuji
Medtronic
Fish and Richardson
Covington
Julphar
Accenture
Johnson and Johnson
Cerilliant

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,119,061

« Back to Dashboard

Summary for Patent: 7,119,061
Title:Dalbavancin compositions for treatment of bacterial infections
Abstract: The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection.
Inventor(s): Stogniew; Martin (Blue Bell, PA)
Assignee: Vicuron Pharmaceuticals, Inc. (King of Prussia, PA)
Application Number:10/834,395
Patent Claim Types:
see list of patent claims
Formulation;

Drugs Protected by US Patent 7,119,061

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc DALVANCE dalbavancin hydrochloride POWDER;IV (INFUSION) 021883-001 May 23, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,119,061

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,143,212 Dalbavancin compositions for treatment of bacterial infections ➤ Sign Up
6,900,175 Methods of administering dalbavancin for treatment of bacterial infections ➤ Sign Up
7,115,564 Stable pharmaceutical compositions of dalbavancin and methods of administration ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Chinese Patent Office
McKinsey
QuintilesIMS
Deloitte
AstraZeneca
Merck
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.